The global extracorporeal membrane oxygenation machine market size was estimated at USD 307.9 million in 2023 and is projected to reach USD 445.7 million by 2030, growing at a CAGR of 5.5% from 2024 to 2030. The primary factor driving this market expansion is the rising incidence of cardiopulmonary diseases and respiratory failures, which increase the demand for advanced life-support technologies like ECMO machines.

For example, data from the Centers for Disease Control and Prevention (CDC) highlights the severity of cardiovascular diseases in the United States, where a person succumbs to cardiovascular-related complications every 37 seconds. This stark statistic emphasizes the critical need for innovative medical devices such as ECMO systems that can provide lifesaving support to patients with severe heart and lung conditions. Chronic obstructive pulmonary disease (COPD), which was one of the leading causes of death in the U.S. in 2020, has also played a significant role in propelling market growth. According to the American Lung Association’s 2022 report, approximately 4.6% of adults—equivalent to 11.7 million people—have been diagnosed with COPD, illustrating the growing prevalence of this debilitating respiratory condition. The increasing number of COPD cases has heightened the demand for advanced respiratory support technologies, thereby fostering significant technological advancements in ECMO devices.

Recent innovations in ECMO technology have involved the integration of cutting-edge components such as hollow pumps, advanced oxygenators, and heparin-coated cannulae, all designed to enhance device performance, efficiency, and patient compatibility. These technological improvements have broadened the applicability of ECMO systems, allowing them to be used effectively across a wide range of complex surgical and critical care procedures.

Additionally, the market growth is supported by the increasing adoption of ECMO machines in hospitals and healthcare facilities worldwide. Awareness programs highlighting the benefits of ECMO therapy have also contributed to greater acceptance and utilization of these machines. Specifically, in the U.S., the number of ECMO programs has surged dramatically in recent years; over one hundred new programs have been launched within the last three to five years alone. This increase has brought the total number of ECMO programs in the country to an estimated 300 to 400, reflecting the expanding integration of ECMO technology in clinical practice. Correspondingly, there has been a rise in the number of ECMO procedures performed globally, further illustrating the growing reliance on these life-saving devices.

A noteworthy development in the ECMO market occurred in July 2022 when Inspira Technologies OXY B.H.N. Ltd. launched the "Liby" System. This advanced life support system is designed specifically to treat patients experiencing life-threatening heart and lung failure. The introduction of the Liby System marks a significant milestone in the evolution of ECMO technology, underscoring ongoing innovation and providing a strong impetus for continued market growth in the years ahead.

Key Market Trends & Insights:

• In 2023, North America emerged as the dominant region in the overall extracorporeal membrane oxygenation (ECMO) machine market, capturing a substantial revenue share of 39.5%. This leadership position reflects the region’s advanced healthcare infrastructure, significant investment in medical technologies, and high adoption rates of innovative life-support systems. Within North America, the United States held the largest share of the market in 2023, driven by its extensive healthcare network, growing incidence of cardiopulmonary diseases, and robust focus on cutting-edge medical research and development.

• When analyzing the market by component, the oxygenators segment stood out as the largest contributor, accounting for 34.61% of the total market share in 2023. This segment is also projected to experience the fastest compound annual growth rate (CAGR) over the forecast period, highlighting the increasing demand for high-performance oxygenation devices that enhance the efficiency and effectiveness of ECMO systems.

• In terms of modality, the veno-arterial (VA) ECMO segment dominated the market with the largest revenue share of 42.2% in 2023. This modality is widely used for patients requiring both cardiac and respiratory support, reflecting its critical role in treating severe cardiopulmonary conditions.

• Looking at applications, the respiratory segment accounted for the largest revenue share of 44.10% in 2023. This significant share underscores the growing utilization of ECMO machines in managing respiratory failures, particularly in conditions such as acute respiratory distress syndrome (ARDS), chronic obstructive pulmonary disease (COPD), and other severe pulmonary ailments. The prominence of this application segment is indicative of the increasing reliance on ECMO technology to support patients with life-threatening respiratory complications.

Order a free sample PDF of the Extracorporeal Membrane Oxygenation Machine Market Intelligence Study, published by Grand View Research.

Market Size & Forecast:

• 2023 Market Size: USD 307.9 Million

• 2030 Projected Market Size: USD 445.7 Million

• CAGR (2024-2030): 5.5%

• North America: Largest market in 2023

• Asia Pacific: Fastest growing market

Key Companies & Market Share Insights:

The competitive landscape within the extracorporeal membrane oxygenation (ECMO) machine market is characterized by the active participation of both well-established industry leaders and dynamic new entrants. These players are leveraging a range of strategic approaches to strengthen their market presence and gain a competitive edge. Key strategies that dominate the market include continuous innovation, aggressive market expansion, and a focus on niche specialization to address specific clinical needs.

Emerging trends such as the development of portable ECMO systems, the integration of telemedicine capabilities, and the incorporation of artificial intelligence (AI) technologies are progressively reshaping the ECMO market environment. These advancements are opening new avenues for improved patient care and operational efficiency. Leading companies in the market are heavily investing in research and development activities to design and introduce portable, miniaturized ECMO devices that offer enhanced mobility and ease of use. Additionally, AI-powered ECMO systems are being developed to provide smarter monitoring, predictive analytics, and personalized treatment options, ultimately aiming to improve clinical outcomes for a diverse range of patients.

Moreover, established ECMO machine manufacturers are strategically focusing on expanding their footprint into emerging and developing regions. These markets are witnessing a rising demand for ECMO therapy due to increasing awareness, growing healthcare infrastructure, and a surge in cardiopulmonary and respiratory conditions. By entering these high-potential markets, leading companies seek to capitalize on untapped opportunities and further drive the growth of the ECMO machine market on a global scale.

Key Players

• Medtronic Plc

• Maquet Holding

• Microport Scientific Corporation

• Terumo Cardiovascular System Corporation

• Medos Medizintechnik

• Nipro Medical Corporation

• LivaNova PLC

• CytoSorbents Corporation

• EUROSETS S.R.L

Explore Horizon Databook – The world's most expansive market intelligence platform developed by Grand View Research.

Conclusion:

The extracorporeal membrane oxygenation (ECMO) market is expected to grow steadily, driven by rising cases of cardiopulmonary and respiratory diseases worldwide. Technological advancements, such as portable and AI-enabled ECMO systems, are enhancing patient care and expanding applications. Increased awareness, adoption in healthcare facilities, and expansion into emerging markets further support the market’s growth trajectory.